• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Henry Schein medical sales lead to Street-beating Q1

Henry Schein medical sales lead to Street-beating Q1

May 5, 2020 By Sean Whooley

Henry ScheinHenry Schein (NSDQ:HSIC) shares got a boost today on first-quarter results that topped the consensus forecast as medical sales boomed.

The Melville, N.Y.-based company posted profits of $130.3 million, or 91¢ per share, on sales of $2.4 billion for the three months ended March 28, 2020, for an 18.7% bottom-line gain on sales growth of 2.9%.

Adjusted to exclude one-time items, earnings per share were 94¢, 21¢ ahead of Wall Street, where analysts were looking for sales of $2.3 billion.

Henry Schein’s dental business took a 4.6% hit as COVID-19 pandemic is leading to the closures of dental practices except for emergency procedures. However, the company’s $800.7 million total in medical sales represented 17.1% growth year over year.

The company also implemented a payroll cost reduction plan with furloughs, reduced work hours, voluntary unpaid time off, suspension of the 401(k) match, and job reductions. Meanwhile, executives took pay cuts ranging from 10% to 100%, according to a news release.

“Due to the speed and severity of the COVID-19 health care and related economic crisis, this is one of the most trying moments in modern history for everyone,” Henry Schein chairman & CEO Stanley Bergman said in the news release. “We took swift and decisive action to reduce our cost structure to best position Henry Schein through this crisis and beyond. I have the utmost confidence in our business strategy, in our leadership team and in all of team Schein. Together we are making critical decisions to manage the company in the interest of all constituents – team Schein, customers, suppliers, investors and society – and in doing so, we are building value for the long-term.”

Henry Schein withdrew its 2020 financial guidance last month amid uncertainties caused by the COVID-19 pandemic.

HSIC shares were up 5.8% at $55.55 per share in early-morning trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was up 1.4%.

Filed Under: Business/Financial News, Dental, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: coronavirus, COVID-19, Henry Schein Inc., Henry Schein Medical

More recent news

  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Preceptis Medical has a new CEO as it advances ear tube tech
  • FDA clears first over-the-counter cuffless blood pressure monitor
  • Mendaera wins FDA clearance for robotic needle placement
  • Johnson & Johnson seeks to have $442 million antitrust verdict tossed out

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy